💊 药物 A-Z 🧬 靶点 🛠 工具 📚 指南
全部药物 药物分类 治疗领域 不良反应
指南 术语表 时间轴
药物比较 药物旅程 药物家族
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Efavirenz

CHEMBL223228 Phase 4 已批准 Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
315.7 g/mol
LogP
4.0
Phase
4

A non-nucleoside reverse transcriptase inhibitor used as part of combination antiretroviral therapy to treat HIV-1 infection. It blocks a viral enzyme essential for HIV to copy its genetic material.

分子量

315.6700 g/mol

LogP

4.00

TPSA

38.30 Ų

Lipinski 五规则

符合

治疗领域

Pancreatic Cancer Cardiovascular Disease Osteoporosis Generalized Anxiety Disorder Non-Alcoholic Fatty Liver Disease Hyperlipidemia Lymphoma Breast Cancer Malaria HIV/AIDS Hepatitis C Tuberculosis Prostate Cancer

作用机制

Inhibits viral reverse transcriptase, blocking the conversion of viral RNA to DNA and preventing viral replication in infected host cells.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

机制

Inhibits viral reverse transcriptase, blocking the conversion of viral RNA to DNA and preventing viral replication in infected host cells.

二维结构

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
O=C1Nc2ccc(Cl)cc2[C@@](C#CC2CC2)(C(F)(F)F)O1

                

                

                
                

                    
InChI

                    
InChI=1S/C14H9ClF3NO2/c15-9-3-4-11-10(7-9)13(14(16,17)18,21-12(20)19-11)6-5-8-1-2-8/h3-4,7-8H,1-2H2,(H,19,20)/t13-/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C14H9ClF3NO2

                    

                    
                    

                        
HBD / HBA

                        
1 / 5

                    

                    
                    

                        
可旋转键数

                        
1

                    

                    
                    
                    

                        
重原子数

                        
21

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
常见问题

                

                    
                    

                        
                        

                            
A non-nucleoside reverse transcriptase inhibitor used as part of combination antiretroviral therapy to treat HIV-1 infection. It blocks a viral enzyme essential for HIV to copy its genetic material.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Inhibits viral reverse transcriptase, blocking the conversion of viral RNA to DNA and preventing viral replication in infected host cells.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Efavirenz is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL223228.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 64139.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
医疗免责声明

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.